Browsed by
Tag: Yeztugo

Lenacapavir: A Twice-Yearly HIV Prevention Injection Approved by the FDA – Promise and Challenges

Lenacapavir: A Twice-Yearly HIV Prevention Injection Approved by the FDA – Promise and Challenges

Lenacapavir: A Twice-Yearly HIV Prevention Injection Approved by the FDA – Promise and Challenges The Food and Drug Administration (FDA) has approved Gilead Sciences’ lenacapavir as a twice-yearly pre-exposure prophylaxis (PrEP) injection, marking a significant advancement in HIV prevention. This approval follows successful Phase III clinical trials demonstrating a remarkably high efficacy rate, exceeding that of daily PrEP regimens. The drug, marketed under the brand name Yeztugo, achieved a 100% prevention rate in cisgender women and a 99.9% prevention rate…

Read More Read More

A Revolutionary HIV Prevention Shot: Yeztugo’s Promise and Challenges

A Revolutionary HIV Prevention Shot: Yeztugo’s Promise and Challenges

A Revolutionary HIV Prevention Shot: Yeztugo’s Promise and Challenges Hey friend, have you heard about Yeztugo? It’s a new HIV prevention injection that’s gotten FDA approval, and it’s pretty groundbreaking. Think of it as the closest thing we’ve got to an HIV vaccine – a powerful shot that offers near-complete protection with just two doses a year! For years, we’ve had daily PrEP pills, but they haven’t fully stemmed the global HIV pandemic. Many people struggle with daily medication adherence,…

Read More Read More